| Literature DB >> 25875314 |
Maria Ausiliatrice Puglisi1, Carlo Cenciarelli2, Valentina Tesori1, Marianna Cappellari3, Maurizio Martini4, Angela Maria Di Francesco5, Ezio Giorda6, Rita Carsetti6, Lucia Ricci-Vitiani3, Antonio Gasbarrini1.
Abstract
Chronic inflammation is a leading cause of neoplastic transformation in many human cancers and especially in colon cancer (CC), in part due to tumour promotion by nitric oxide (NO) generated at inflammatory sites. It has also been suggested that high NO synthesis, secondary to inducible NO synthase (iNOS) expression, is a distinctive feature of cancer stem cells (CSCs), a small subset of tumour cells with self-renewal capacity. In this study we explored the contribution of NO to the development of colon CSC features and evaluated potential strategies to treat CC by modulating NO production. Our data show an integral role for endogenous NO and iNOS activity in the biology of colon CSCs. Indeed, colon CSCs with high endogenous NO production (NO(high)) displayed higher tumourigenic abilities than NO(low) fractions. The blockade of endogenous NO availability, using either a specific iNOS inhibitor or a genetic knock-down of iNOS, resulted in a significant reduction of colon CSC tumourigenic capacities in vitro and in vivo. Interestingly, analysis of genes altered by iNOS-directed shRNA showed that the knockdown of iNOS expression was associated with a significant down-regulation of signalling pathways involved in stemness and tumour progression in colon CSCs. These findings confirm that endogenous NO plays an important role in defining the stemness properties of colon CSCs through cross-regulation of several cellular signalling pathways. This discovery could shed light on the mechanisms by which NO induces the growth and invasiveness of CC, providing new insights into the link between inflammation and colon tumourigenesis.Entities:
Keywords: CD133; cancer stem cells; colon cancer; iNOS; nitric oxide
Mesh:
Substances:
Year: 2015 PMID: 25875314 DOI: 10.1002/path.4545
Source DB: PubMed Journal: J Pathol ISSN: 0022-3417 Impact factor: 7.996